427 related articles for article (PubMed ID: 31730504)
1. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
[TBL] [Abstract][Full Text] [Related]
2. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
Darville N; van Heerden M; Mariën D; De Meulder M; Rossenu S; Vermeulen A; Vynckier A; De Jonghe S; Sterkens P; Annaert P; Van den Mooter G
J Control Release; 2016 May; 230():95-108. PubMed ID: 27067365
[TBL] [Abstract][Full Text] [Related]
3. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
[TBL] [Abstract][Full Text] [Related]
5. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
Carter NJ
Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
[TBL] [Abstract][Full Text] [Related]
6. Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia.
Lamb YN; Keating GM
Drugs; 2016 Oct; 76(16):1559-1566. PubMed ID: 27699643
[TBL] [Abstract][Full Text] [Related]
7. Three-month paliperidone palmitate - a new treatment option for schizophrenia.
Bernardo M; Bioque M
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):899-904. PubMed ID: 27206330
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia.
Shimizu H; Neyens M; De Meulder M; Gopal S; Tsukamoto Y; Samtani MN; Remmerie B
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):224-234. PubMed ID: 31876117
[TBL] [Abstract][Full Text] [Related]
9. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.
Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
CNS Drugs; 2017 Apr; 31(4):273-288. PubMed ID: 28258365
[TBL] [Abstract][Full Text] [Related]
10. A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly.
Geerts H; Spiros A; Roberts P; Alphs L
Schizophr Res; 2018 Jul; 197():261-268. PubMed ID: 29395607
[TBL] [Abstract][Full Text] [Related]
11. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.
Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
Clin Pharmacokinet; 2017 Apr; 56(4):421-433. PubMed ID: 27743205
[TBL] [Abstract][Full Text] [Related]
13. Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
T'jollyn H; Venkatasubramanian R; Neyens M; Gopal S; Russu A; Nandy P; Perez-Ruixo JJ; Ackaert O
Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):491-506. PubMed ID: 38769284
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.
Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907
[TBL] [Abstract][Full Text] [Related]
15. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
Morris MT; Tarpada SP
Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
[TBL] [Abstract][Full Text] [Related]
16. Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients.
Tveito M; Høiseth G; Haslemo T; Molden E; Smith RL
Eur J Clin Pharmacol; 2021 Aug; 77(8):1201-1208. PubMed ID: 33616704
[TBL] [Abstract][Full Text] [Related]
17. Model-Informed Drug Development for Long-Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium.
Sharan S; Fang L; Lukacova V; Chen X; Hooker AC; Karlsson MO
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):220-228. PubMed ID: 33624456
[No Abstract] [Full Text] [Related]
18. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
19. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
[TBL] [Abstract][Full Text] [Related]
20. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
